Arcutis Biotherapeutics (ARQT) said Wednesday that the US Food and Drug Administration has accepted its supplemental new drug application for Zoryve to treat mild to moderate atopic dermatitis in children two to five years old.
The medical dermatology company said the FDA has set a Prescription Drug User Fee Act target action date of Oct. 13.
Shares of Arcutis Biotherapeutics were up almost 9% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.